Fulcrum Therapeutics, Inc.
FULC
$6.92
-$0.51-6.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.77% | -13.29% | 2.03% | -6.56% | 23.64% |
| Total Depreciation and Amortization | 0.29% | 0.58% | -2.55% | -4.34% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.28% | 54.97% | -21.08% | 48.04% | -42.51% |
| Change in Net Operating Assets | -77.86% | 70.27% | 701.79% | 89.35% | -410.73% |
| Cash from Operations | -18.38% | -2.68% | 9.42% | 8.97% | 12.12% |
| Capital Expenditure | -76.67% | -38.46% | -- | -- | -1,115.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -104.76% | 33.60% | 1,901.54% | -131.19% | -42.98% |
| Cash from Investing | -105.64% | 33.58% | 1,893.18% | -134.38% | -48.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 262,871.88% | -78.74% | -- | -- | -86.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 262,871.88% | -78.74% | -- | -- | -86.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,253.88% | 983.57% | 102.58% | -11.21% | -2.35% |